A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children

References

• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi:10.1016/S0140-6736(20)31286-1
   PubMed Web of Science ®Google Scholar
• Chovatiya R. Atopic Dermatitis (Eczema). JAMA. 2023;329(3):268. doi:10.1001/jama.2022.21457
   PubMedGoogle Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi:10.1111/jdv.14891
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–28.e2. doi:10.1016/j.anai.2020.12.020
   PubMed Web of Science ®Google Scholar
• Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006;118(1):214–219. doi:10.1016/j.jaci.2006.05.004
   PubMed Web of Science ®Google Scholar
• Osawa R, Akiyama M, Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergology Int. 2011;60(1):1–9. doi:10.2332/allergolint.10-RAI-0270
   PubMedGoogle Scholar
• Demessant-Flavigny AL, Connétable S, Kerob D, Moreau M, Aguilar L, Wollenberg A. Skin microbiome dysbiosis and the role of Staphylococcus aureus in atopic dermatitis in adults and children: a narrative review. J Eur Acad Dermatol Venereol. 2023;37(Suppl 5):3–17. doi:10.1111/jdv.19125
   PubMedGoogle Scholar
• Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi:10.1038/nrd4624
   PubMed Web of Science ®Google Scholar
• Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20(5):448–474. doi:10.1038/s41423-023-00992-4
   PubMed Web of Science ®Google Scholar
• Nowowiejska J, Baran A, Flisiak I. Lipid Alterations and Metabolism Disturbances in Selected Inflammatory Skin Diseases. Int J Mol Sci. 2023;24(8):7053. doi:10.3390/ijms24087053
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144–151. doi:10.1016/j.anai.2019.04.020
   PubMed Web of Science ®Google Scholar
• Barbarot S, Silverberg JI, Gadkari A, et al. The Family Impact of Atopic Dermatitis in the Pediatric Population: results from an International Cross-sectional Study. J Pediatr. 2022;246:220–6.e5. doi:10.1016/j.jpeds.2022.04.027
   PubMed Web of Science ®Google Scholar
• Paller A, Jaworski JC, Simpson EL, et al. Major Comorbidities of Atopic Dermatitis: beyond Allergic Disorders. Am j Clin Dermatol. 2018;19(6):821–838. doi:10.1007/s40257-018-0383-4
   PubMed Web of Science ®Google Scholar
• Davidson WF, Leung DYM, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: mechanisms and interventions”. J Allergy Clin Immunol. 2019;143(3):894–913. doi:10.1016/j.jaci.2019.01.003
   PubMed Web of Science ®Google Scholar
• Murota H, Koike Y, Morisaki H, Matsumoto M, Takenaka M. Exacerbating factors and disease burden in patients with atopic dermatitis. Allergology Int. 2022;71(1):25–30. doi:10.1016/j.alit.2021.10.002
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Marseglia A, et al. Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents. Paediatric Drugs. 2020;22(3):295–310. doi:10.1007/s40272-020-00387-2
   PubMed Web of Science ®Google Scholar
• Harb H, Chatila TA. Mechanisms of Dupilumab. Clin exp allerg. 2020;50(1):5–14. doi:10.1111/cea.13491
   PubMed Web of Science ®Google Scholar
• Cabanillas B. Dupilumab for Atopic Dermatitis-From Clinical Trials to Molecular and Cellular Mechanisms. Dermatitis. 2022. doi:10.1097/DER.0000000000000905
   PubMed Web of Science ®Google Scholar
• Mastorino L, Viola R, Panzone M, et al. Dupilumab induces a rapid decrease of pruritus in adolescents: a pilot real-life study. Dermatologic Therapy. 2021;34(6):e15115. doi:10.1111/dth.15115
   PubMed Web of Science ®Google Scholar
• Mastorino L, Cantafio Duò VL, Vecco C, et al. Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks. J Eur Acad Dermatol Venereol. 2022;36(12):e1021–e3. doi:10.1111/jdv.18427
   PubMed Web of Science ®Google Scholar
• Miniotti M, Ribero S, Mastorino L, et al. Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: data up to 3 years. Exp dermatol. 2023;32(6):852–858. doi:10.1111/exd.14786
   PubMed Web of Science ®Google Scholar
• LaPorte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132(2):259–272. doi:10.1016/j.cell.2007.12.030
   PubMed Web of Science ®Google Scholar
• Andrews AL, Holloway JW, Holgate ST, Davies DE. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Iimmunol. 2006;176(12):7456–7461. doi:10.4049/jimmunol.176.12.7456
   PubMed Web of Science ®Google Scholar
• Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. doi:10.1111/all.14151
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Romagnuolo M, Maronese CA, et al. Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis. Therapeutic Adv Chronic Dis. 2021;12:20406223211058332. doi:10.1177/20406223211058332
   Web of Science ®Google Scholar
• Berdyshev E, Goleva E, Bissonnette R, et al. Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis. Allergy. 2022;77(11):3388–3397. doi:10.1111/all.15432
   PubMed Web of Science ®Google Scholar
• Callewaert C, Nakatsuji T, Knight R, et al. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. J Investigative Dermatol. 2020;140(1):191–202.e7. doi:10.1016/j.jid.2019.05.024
   PubMed Web of Science ®Google Scholar
• Simpson EL, Schlievert PM, Yoshida T, et al. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J Allergy Clin Immunol. 2023.
   Web of Science ®Google Scholar
• Hartmann J, Moitinho-Silva L, Sander N, et al. Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis. Allergy. 2023;78(8):2290–2300. doi:10.1111/all.15742
   PubMed Web of Science ®Google Scholar
• Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2022;400(10356):908–919. doi:10.1016/S0140-6736(22)01539-2
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. doi:10.1016/j.jaad.2020.06.054
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: a Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44–56.
   PubMed Web of Science ®Google Scholar
• Butala S, Paller AS. Biologics in the management of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(3):681–685. doi:10.1016/j.jaci.2023.01.010
   PubMed Web of Science ®Google Scholar
• Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013;68(8):974–982. doi:10.1111/all.12184
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Neri I, et al. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: a Multicentre, Real-Life Study. Paediatric Drugs. 2022;24(6):671–678. doi:10.1007/s40272-022-00531-0
   PubMed Web of Science ®Google Scholar
• Wang A, Zhou Y, Luo Y, et al. High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis. Front Immunol. 2023;14:1160710.
   PubMed Web of Science ®Google Scholar
• Zhou B, Peng C, Cao Q, Wang J, Chen X, Li J. Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: a Chinese real-world study. J Eur Acad Dermatol Venereol. 2023;38(1):e35–e38. doi:10.1111/jdv.19409
   PubMedGoogle Scholar
• Patruno C, Fabbrocini G, Lauletta G, et al. A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years. J Dermatol Treatment. 2023;34(1):2246602. doi:10.1080/09546634.2023.2246602
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Potestio L, et al. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis. Dermatologic Therapy. 2022;35(8):e15588. doi:10.1111/dth.15588
   PubMed Web of Science ®Google Scholar
• Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis. J Am Acad Dermatol. 2022;86(3):628–636. doi:10.1016/j.jaad.2021.06.017
   PubMed Web of Science ®Google Scholar
• Kychygina A, Cassagne M, Tauber M, et al. Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases. Clin Rev Allergy Immunol. 2022;62(3):519–533. doi:10.1007/s12016-022-08934-0
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Rosmarin D, Bieber T, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br j dermatol. 2019;181(1):196–197. doi:10.1111/bjd.17703
   PubMed Web of Science ®Google Scholar
• Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J Dermatol Treatment. 2022;33(7):3028–3033. doi:10.1080/09546634.2022.2102121
   PubMed Web of Science ®Google Scholar
• Bansal A, Simpson EL, Paller AS, et al. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Am j Clin Dermatol. 2021;22(1):101–115. doi:10.1007/s40257-020-00577-1
   PubMed Web of Science ®Google Scholar
• Treister AD, Kraff-Cooper C, Lio PA. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. JAMA Dermatol. 2018;154(10):1208–1211. doi:10.1001/jamadermatol.2018.2690
   PubMed Web of Science ®Google Scholar
• Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br j dermatol. 2019;181(3):459–473. doi:10.1111/bjd.17869
   PubMed Web of Science ®Google Scholar
• Tao Z, Liu W, Chen Q, et al. Blocking Th2 Signaling Pathway Alleviates the Clinical Symptoms and Inflammation in Allergic Conjunctivitis. Invest Ophthalmol Visual Sci. 2023;64(10):30. doi:10.1167/iovs.64.10.30
   PubMed Web of Science ®Google Scholar
• Han H, Cummings S, Shade KC, et al. Cellular mechanisms and effects of IL-4 receptor blockade in experimental conjunctivitis evoked by skin inflammation. JCI Insight. 2023;8(3). doi:10.1172/jci.insight.163495
   Web of Science ®Google Scholar
• Huang J, Choo YJ, Smith HE, Apfelbacher C. Quality of life in atopic dermatitis in Asian countries: a systematic review. Archives of Dermatological Res. 2022;314(5):445–462. doi:10.1007/s00403-021-02246-7
   PubMed Web of Science ®Google Scholar
• Ramirez FD, Chen S, Langan SM, et al. Association of Atopic Dermatitis With Sleep Quality in Children. JAMA Pediatrics. 2019;173(5):e190025. doi:10.1001/jamapediatrics.2019.0025
   PubMed Web of Science ®Google Scholar
• Patel KR, Immaneni S, Singam V, Rastogi S, Silverberg JI. Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(2):402–410. doi:10.1016/j.jaad.2018.08.063
   PubMed Web of Science ®Google Scholar
• Stingeni L, Bianchi L, Antonelli E, et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022;36(8):1292–1299. doi:10.1111/jdv.18141
   PubMed Web of Science ®Google Scholar
• Stingeni L, Bianchi L, Antonelli E, et al. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(3):e384–e8. doi:10.1111/jdv.18648
   PubMed Web of Science ®Google Scholar
• Lasek A, Bellon N, Mallet S, et al. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice. J Eur Acad Dermatol Venereol. 2022;36(12):2423–2429. doi:10.1111/jdv.18450
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am j Clin Dermatol. 2022;23(3):365–383. doi:10.1007/s40257-022-00683-2
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40–45. doi:10.1016/j.anai.2020.07.026
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: a Cost-Utility Analysis. J Drugs Dermatol. 2018;17(7):750–756.
   PubMed Web of Science ®Google Scholar
• Miyaji Y, Yang L, Yamamoto-Hanada K, Narita M, Saito H, Ohya Y. Earlier aggressive treatment to shorten the duration of eczema in infants resulted in fewer food allergies at 2 years of age. The Journal of Allergy and Clinical Immunology in Practice. 2020;8(5):1721–4.e6. doi:10.1016/j.jaip.2019.11.036
   PubMed Web of Science ®Google Scholar
• Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756–766. doi:10.1016/j.jaci.2022.08.026
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Simpson EL, Cork MJ, et al. Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years. Dermatol Ther. 2023;13(9):1987–2000. doi:10.1007/s13555-023-00960-w
   Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Simpson EL, Chen Z, Zhang A, Shumel B. Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. Dermatol Ther. 2022;12(1):223–231. doi:10.1007/s13555-021-00638-1
   Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older. Dermatol Ther. 2021;11(5):1643–1656. doi:10.1007/s13555-021-00568-y
   Web of Science ®Google Scholar